arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ANI PHARMACEUTICALS INC

ANIP
$74.42 ▼ -3.44 (-4.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
71
Health
Good
Bullish
auto_awesome

Analytical Summary

ANI PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.6B
Dividend Yield
Revenue Growth 25.9%
Op. Margin 15.2%
ROIC 3.1%
FCF / Share $2.53
Trailing P/E 68.3x
Price / Book 2.6x
FCF Yield 3.4%
Debt / Equity 0.47
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$266.04M
↑ +25.9%
Net Income Profit after all expenses
$24.71M
↑ +189.1%
Operating Margin Operating profit as % of sales
15.2%
↓ -7.1% 62th
FCF / Share Free cash flow per share
$2.53
↑ +1.3%
Long-Term Debt Long-term obligations
$280.15M
↓ -2.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
68
Returns
79
Financial Health
58
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters